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ABSTRACT 
 
Background: Atrial fibrillation (AF) is common and has a substantial genetic basis. 
Identification of individuals at greatest AF risk could minimize the incidence of cardioembolic 
stroke.  
Methods: To determine whether genetic data can stratify risk for development of AF, we 
examined associations between AF genetic risk scores and incident AF in five prospective 
studies comprising 18,919 individuals of European ancestry. We examined associations 
between AF genetic risk scores and ischemic stroke in a separate study of 509 ischemic stroke 
cases (202 cardioembolic [40%]) and 3,028 controls. Scores were based on 11 to 719 common 
variants (≥5%) associated with AF at P-values ranging from <1x10-3 to <1x10-8 in a prior 
independent genetic association study.   
Results: Incident AF occurred in 1,032 (5.5%) individuals. AF genetic risk scores were 
associated with new-onset AF after adjusting for clinical risk factors. The pooled hazard ratio for 
incident AF for the highest versus lowest quartile of genetic risk scores ranged from 1.28 (719 
variants; 95%CI, 1.13-1.46; P=1.5x10-4) to 1.67 (25 variants; 95%CI, 1.47-1.90; P=9.3x10-15). 
Discrimination of combined clinical and genetic risk scores varied across studies and scores 
(maximum C statistic, 0.629-0.811; maximum ΔC statistic from clinical score alone, 0.009-
0.017). AF genetic risk was associated with stroke in age- and sex-adjusted models. For 
example, individuals in the highest quartile of a 127-variant score had a 2.49-fold increased 
odds of cardioembolic stroke, versus those in the lowest quartile (95%CI, 1.39-4.58; P=2.7x10-
3). The effect persisted after excluding individuals (n=70) with known AF (odds ratio, 2.25; 
95%CI, 1.20-4.40; P=0.01).  
Conclusions: Comprehensive AF genetic risk scores were associated with incident AF beyond 
clinical AF risk factors, with magnitudes of risk comparable to other clinical risk factors, though 
offered small improvements in discrimination. AF genetic risk was also associated with 
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cardioembolic stroke in age- and sex-adjusted analyses. Efforts to determine whether AF 
genetic risk may improve identification of subclinical AF or distinguish stroke mechanisms are 
warranted.  
 
 
 
Key words: atrial fibrillation, stroke, genetic, risk, prediction
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CLINICAL PERSPECTIVE 
 
What is new? 
 Studies have identified several genetic loci associated with AF, yet it is unclear whether 
genetic profiling can identify individuals at greatest risk for AF or cardioembolic stroke. 
 Using genome-wide data from an independent large-scale analysis, we tested 
comprehensive AF genetic risk scores for association with new-onset AF in five 
prospective studies, and with stroke in a separate stroke case-control sample. 
 Genetic risk scores were associated with AF beyond established clinical risk factors, but 
improved prediction minimally.  
 AF genetic risk was strongly associated with cardioembolic stroke, suggesting that 
elevated AF genetic risk might serve as a surrogate for thromboembolism from AF.  
 
What are the clinical implications? 
 Our findings underscore the complementary information provided by both clinical and 
genetic factors. 
 However, since genetic information currently affords small improvements in 
discrimination of AF risk, widespread use of genetic risk profiling does not need to be 
incorporated into routine clinical decision-making at this time. 
 Our findings raise the possibility that AF genetic risk may serve as a signature for 
strokes caused by thromboembolism from AF.  
 Future studies are warranted to determine whether AF genetic risk can distinguish stroke 
etiologic mechanisms, or identify individuals with strokes that have subclinical AF. 
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Atrial fibrillation (AF) is a heritable1 and common arrhythmia associated with substantial 
morbidity and economic costs.2 Approximately one in five ischemic strokes are attributable to 
cardioembolic events from AF.3 Strokes due to AF are associated with more disability and 
mortality than strokes from other etiologies.4 Since many strokes caused by AF are preventable 
with effective anticoagulation,5 and because AF may be undetected in some individuals, there is 
a critical need to identify those at greatest risk for the arrhythmia.  
In recent years, risk models for AF prediction have been developed based on clinical 
and demographic variables.6-9 We and others have identified common genetic variants 
associated with AF,10-17 and some of these have been associated with incident AF18 and 
ischemic stroke19 after adjustment for clinical risk factors. Yet it remains unclear whether a 
comprehensive AF genetic risk score can facilitate identification of individuals at greatest risk for 
AF or cardioembolic stroke, since such individuals might benefit from stroke prevention efforts.  
We therefore sought to determine whether comprehensive AF genetic risk scores are 
associated with incident AF beyond clinical risk factors, and might facilitate identification of 
individuals at greatest risk for the arrhythmia. In addition, we sought to examine whether AF 
genetic risk is associated with ischemic stroke, and in particular, cardioembolic stroke.  
 
METHODS 
Participants 
We examined the association between AF genetic risk and incident AF in five prospective 
studies. Briefly, these studies were the Malmö Diet and Cancer Study (MDCS),20 the Multi-
Ethnic Study of Atherosclerosis (MESA),21 the Prevention of Renal and Vascular Endstage 
Disease (PREVEND) study,22 the PROspective Study of Pravastatin in the Elderly at Risk 
(PROSPER),23 and the Vanderbilt University de-identified DNA biobank (BioVU).24 We also 
examined the association between AF genetic risk and stroke in the Massachusetts General 
Hospital Genes Associated with Stroke Risk and Outcomes Study (MGH-GASROS), a hospital-
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based case-control study of acute ischemic stroke patients (enrolled between July 2000 and 
2011) and referent individuals from the Myocardial Infarction Genetics Consortium (without a 
history of myocardial infarction).25,26 All stroke cases in MGH-GASROS underwent etiologic 
stroke subtyping in a uniform fashion, according to the Trial of Org 10172 in Acute Stroke 
Treatment (TOAST) criteria.27 Descriptions of each study are provided in the online 
supplement, including details on clinical risk factor and outcome ascertainment, genotyping, 
and imputation. For all analyses, samples were restricted to individuals of self-reported 
European ancestry. Each study was approved by its Institutional Review Board, and participants 
provided written informed consent.  
 
AF genetic risk 
To estimate genetic risk using a minimal set of single nucleotide polymorphisms (SNPs), we 
selected uncorrelated SNPs by pruning28 2.2 million HapMap variants included in a prior 
independent meta-analysis of genome-wide association studies for AF from the AFGen 
consortium (6,707 individuals with and 53,436 without AF).15 We considered all SNPs that had 
allele frequencies ≥ 5% and were nominally associated with AF (P<1x10-3). We then selected 
the most significantly associated SNP within a given 250 kilobase locus that was not in linkage 
disequilibrium with another more significantly associated SNP at that locus (r2<0.1). In total, 719 
uncorrelated SNPs were selected for construction of genetic risk scores (Supplemental Table 
1). 
For each individual, we calculated AF genetic risk scores by summing the dosage of 
each AF risk allele (ranging from 0 to 2) weighted by the natural logarithm of the relative risk for 
each SNP. Weights were determined in our earlier, independent meta-analysis.15 Thus, a 
genetic risk score for an individual is a single linear predictor variable. Since the optimum 
number of risk alleles that should be used for genetic risk scores has not been fixed, we 
constructed seven different scores for each individual based on the strength of association 
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between each SNP and AF in the earlier analysis.15 We selected the seven different significance 
thresholds a priori: P<1x10-3, <1x10-4, <1x10-5, <1x10-6, <1x10-7, <5x10-8, and <1x10-8. Liberal 
inclusion of SNPs was motivated by observations that uncorrelated SNPs demonstrating less 
significant associations with a trait may still explain a substantial proportion of the heritability of 
the trait.29-32  
 
Statistical analysis 
Within each prospective study, we used proportional hazards regression to examine 
associations between the different AF genetic risk scores and incident AF over a 5-year time 
horizon. For all incident AF analyses, person-time in each cohort began at DNA collection or 
baseline enrollment. Individuals were treated as censored at the time of death or loss to follow-
up. Models were adjusted for variables included in a previously validated composite risk score 
for 5-year AF risk prediction (CHARGE-AF risk score).9 The composite CHARGE-AF risk score 
included age, height, weight, systolic and diastolic blood pressures, smoking status, 
antihypertensive medication use, diabetes status, heart failure status, myocardial infarction 
status, electrocardiographic evidence of left ventricular hypertrophy, and PR interval. 
Electrocardiographic variables that were not available were omitted from the scores on a study-
by-study basis (left ventricular hypertrophy was unavailable in MDCS, MESA, PREVEND, and 
PROSPER; PR interval was unavailable in MDCS, PREVEND, PROSPER, and BioVU). Race 
was not included in the models since we restricted our sample to individuals of European 
ancestry. Proportional hazards assumptions were verified with multiplicative interaction terms 
between covariates and the natural logarithm of follow-up time. 
For each model, we calculated goodness-of-fit statistics using Akaike’s Information 
Criterion, a penalized likelihood metric in which lower values indicate better fit.33 We also 
assessed discrimination using the C statistic for time-to-event data.34 Calibration of the 
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prediction models was assessed using the Hosmer-Lemeshow statistic modified for survival 
analysis.35 
In exploratory analyses we combined model parameters from each study by use of an 
inverse variance random-effects meta-analysis approach, and calculated heterogeneity using 
the I2 statistic.36 We utilized a random-effects approach owing to inherent differences in study 
design (see supplemental methods for details). We then multiplied the summary score beta 
coefficient by the difference between the 12.5th and 87.5th percentiles of AF genetic risk scores 
from a common reference population (Supplemental Table 2). The resulting values estimate 
the relative risk comparing individuals in the highest and lowest quartiles across each study and 
score, in a standard fashion. The common reference population used was a pooled sample of 
12,801 individuals from the Framingham Heart Study (n=2,551),37 the Atherosclerosis Risk in 
Communities Study (n=7,278),38 and the Cardiovascular Health Study (n=2,972)39 with genome-
wide genotyping data.15  
We then examined whether AF genetic risk was associated with AF, ischemic stroke, 
and cardioembolic stroke in MGH-GASROS using multivariable logistic regression. Since 
several of the identified pruned AF SNPs were not available in the MGH-GASROS sample, we 
utilized proxy SNPs on the basis of linkage disequilibrium when available (Supplemental Table 
1). The number of SNPs in some genetic risk scores differed slightly based on inability to 
identify proxies. Models were adjusted for age and sex only, because extended clinical 
information was not available in the referent participants. Since AF was ascertained only in 
stroke cases, we assumed that AF was not present among referents for analyses of AF (an 
assumption that would be expected to bias the results toward a null association between 
genetic risk and AF due to the potential for misclassified individuals who have AF among the 
referent sample). We then examined associations between AF genetic risk and ischemic stroke, 
as well as the association with the TOAST cardioembolic stroke classification (a subset of 
ischemic stroke). We utilized the same referent sample set for analyses of ischemic and 
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cardioembolic stroke. Because AF may occur as a subclinical condition, we examined in 
exploratory analyses whether AF genetic risk scores were associated with stroke in individuals 
without known AF, again assuming that referent subjects did not have AF.  
 None of the studies in our analysis of incident AF were used in any aspect of the 
derivation of genetic risk or the CHARGE-AF scores. The a priori significance threshold for all 
analyses was P<0.05 using two-sided tests. Meta-analyses were conducted using the rmeta40 
package in R.41 Other software utilized for analyses is described in the supplement.  
 
RESULTS 
AF genetic risk scores and incident AF 
Among 18,919 individuals across all studies in our analyses of incident AF, the mean age 
ranged from 58-75 years, and the proportion of women ranged from 47-52%. During the 5-year 
follow-up window, 1,032 (5.5%) individuals developed incident AF (Table 1). AF genetic risk 
scores were associated with incident AF after accounting for clinical risk factors (Supplemental 
Figure 1 and Supplemental Table 3). Heterogeneity of effect estimates was modest between 
studies. Generally, the models with the best fit included scores with between 25 and 129 SNPs, 
as indicated by the AIC (Supplemental Table 3).  
For each of the seven groups of genetic risk scores, we estimated hazard ratios 
comparing individuals in the highest quartile of each genetic risk score with those in the lowest 
quartile. Across the genetic risk scores, those in the highest quartile had a 1.28-fold (719 SNPs; 
95% CI, 1.13-1.46; P=1.5x10-4) to 1.67-fold (25 SNPs; 95%CI, 1.47-1.90; P=9.3x10-15) 
increased hazard for AF (Figure 1). C statistics for the clinical risk factor model without AF 
genetic risk scores ranged from 0.615 to 0.802 across cohorts (Supplemental Table 3). Adding 
AF genetic risk scores to the clinical risk factor model resulted in a maximum change in the C-
statistic of between 0.009 and 0.017 across all cohorts and scores. The maximum change of up 
to 0.065 in PROSPER may have been driven by the small sample size and was considered an 
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outlier. To illustrate the impact of clinical and genetic risk on incident AF detection, we plotted 
the cumulative incidence of AF stratified by dichotomized clinical risk, as well by both clinical 
and genetic risk together, for one representative study (MDCS) in Supplemental Figure 2.  
 
AF genetic risk scores and ischemic stroke 
We examined the association between AF genetic risk scores and stroke among 509 
independent individuals with stroke from MGH-GASROS and 3,028 controls (Table 2). Among 
the stroke cases, 202 (40%) were classified as having had a cardioembolic stroke by TOAST 
criteria. In total, 87 (17%) individuals with ischemic stroke had documented AF.  
In MGH-GASROS, modest associations between AF genetic risk scores and AF, 
ischemic stroke (all subtypes), and the subset of cases with cardioembolic stroke were 
observed using continuous genetic risk scores (Supplemental Table 4). The most significantly 
associated score with AF, as judged by the score with the smallest P-value, occurred with a 
score constructed from 127 SNPs, corresponding to SNPs with P values <1x10-4 for 
associations with AF in the prior independent AFGen analysis.15 Individuals in the highest 
quartile of the 127-SNP genetic risk score had a 3.13-fold (95%CI, 1.47-7.21; P=0.005) 
increased odds of AF relative to those in the lowest quartile.  
In the analysis of ischemic stroke cases and referent individuals, AF genetic risk scores 
were also modestly associated with both ischemic stroke (all subtypes) and cardioembolic 
stroke (Supplemental Table 3). Those in the highest quartile of the 127-SNP genetic risk score 
had a 1.73-fold (95%CI, 1.15-2.61; P=9.0x10-3) increased odds of ischemic stroke, and a 2.49-
fold (95%CI, 1.39-4.58; P=2.7x10-3) increased odds of cardioembolic stroke (after excluding 
other stroke subtypes, Figure 2). After omitting the 87 stroke cases with known AF (70 of whom 
had cardioembolic strokes), the associations between AF genetic risk and both ischemic and 
cardioembolic stroke remained but were slightly attenuated (Supplemental Table 5). 
Specifically, the relative odds of ischemic stroke comparing those in the highest with those in 
 Page 12 of 33 
the lowest quartile of a 127-SNP AF genetic risk score were 1.55 (95%CI, 1.03-2.36; P=0.04) 
for ischemic stroke, and 2.25 (95%CI, 1.20-4.40; P=0.01) for cardioembolic stroke (Figure 2). 
 
DISCUSSION 
In our analysis of nearly 19,000 individuals of European ancestry, scores reflecting the burden 
of AF risk alleles were associated with 5-year risks of new-onset AF, after adjusting for clinical 
risk factors. Individuals in the highest quartile of the genetic scores had up to a 67% higher risk 
of new-onset AF than those in the lowest quartile, although incremental discrimination beyond 
clinical risk factors was small regardless of the number of SNPs included in the genetic risk 
score. In an independent sample, individuals in the highest quartile of a score comprised of 127 
AF-associated genetic markers had roughly two-fold higher odds of cardioembolic stroke, 
compared with those in the lowest quartile after adjustment for age and sex. Associations 
between AF genetic risk scores and cardioembolic stroke persisted after excluding individuals 
with known AF.  
Our findings support and extend prior observations that AF genetic risk is associated 
with both AF and stroke. We previously observed an association between familial AF and 
incident AF in the Framingham Heart Study, beyond associations for clinical risk factors.1 
Subsequently, we observed an approximately 4 to 5-fold gradient in risk between those in the 
highest versus lowest tails of a 12-SNP AF genetic risk score (based on nine loci) in case-
referent and cohort studies.16 The Women’s Genome Health Study reported an association 
between an AF genetic risk score based on 12 SNPs and occurrence of incident AF,18 although 
the AF-associated SNPs used in the analysis were identified in a previous discovery study using 
the same study sample. Earlier work also described associations between the top AF-
associated variants on chromosomes 4q25 and 16q22 with ischemic (and in particular, 
cardioembolic) stroke.13,26,42-44 Recently, we and others reported a 2-fold increased hazard of AF 
and a 1.23-fold increased hazard of ischemic stroke for individuals in the highest versus lowest 
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quintiles of scores based on a 12-SNP genetic risk model during an average follow-up of 14 
years in the MDCS, subjects of which were included in the present analysis of incident AF.19 
Thus, by using well-characterized independent study samples, our current findings extend prior 
reports that AF genetic risk is associated with incident AF, as well as ischemic stroke.  
Our observations have three major implications. First, our finding that AF genetic risk is 
associated with incident AF beyond the effects observed for accepted clinical risk factors 
highlights the ability of common genetic variation to capture complementary information. Indeed, 
the 28%-67% increased risk of AF among individuals in the highest versus the lowest quartile of 
genetic risk is comparable to the magnitude of risk conferred by traditional clinical risk factors for 
AF.9 Nevertheless, even by including a large number of genetic variants and assessing 
associations with incident AF in large cohorts, the magnitudes of risk associated with genetic 
risk improved discrimination minimally beyond clinical factors. Such findings underscore the 
challenges of improving clinical prediction models even when including highly associated 
predictors.45  
Second, our observations, coupled with prior findings that AF genetic risk may be 
preferentially associated with cardioembolic stroke,13,42,43 raise the possibility that AF genetic 
risk may serve as a signature for strokes caused by thromboembolism due to AF. Our 
observation that AF genetic risk was associated with an increased risk of cardioembolic stroke 
even after excluding individuals with known AF is consistent with the hypothesis that AF genetic 
risk may be a clinically relevant marker for subclinical, or previously undiagnosed, AF. Although 
AF genetic risk has a limited impact beyond knowledge of clinical risk factors on AF prediction 
over a 5-year time horizon, it is possible that such genetic profiling may provide insights into 
stroke mechanisms and therefore screening and treatment options for secondary prevention. 
Future analyses are warranted to determine if AF genetic risk discriminates effectively between 
different stroke subtypes, to assess whether AF genetic risk can identify cryptogenic stroke 
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patients at elevated risk for recurrent stroke due to AF, and whether estimating AF risk can 
enhance secondary stroke prevention efforts. 
Third, our observation that genetic risk scores constructed from liberally selected SNPs 
were nevertheless associated with AF and AF-related stroke emphasizes the polygenic nature 
of AF. Therefore, true AF susceptibility variants are likely to exist even though they may not 
meet the stringent genome-wide significance criteria currently utilized. Future genetic discovery 
efforts in larger samples with better power are warranted to identify additional AF susceptibility 
signals. Indeed, since publication of the most recent AFGen meta-analysis,15 additional bona 
fide subthreshold AF signals have been identified, and some appear to be associated with 
stroke.17 It remains to be determined whether future assessment of AF genetic risk based on 
associations derived from larger samples will enhance specificity of prediction models.  
Our study should be interpreted in the context of the study design. First, all participants 
were of European descent, and therefore our findings may not be generalizable to individuals of 
other ancestral groups. Second, the genetic risk models were linear in nature with a single 
predictor variable, and did not account for potential non-additive genetic effects, interactions 
between genetic variants, or interactions between genetic variants and environmental factors. 
Additional modeling methods, including penalized regression or other techniques, may yield 
more precise genetic risk models. Third, other important determinants of AF risk were not 
available in our study, including plasma biomarkers such as brain natriuretic peptide.46 Similarly, 
in analyses of ischemic stroke, clinical covariates beyond age and sex were unavailable, so we 
could not evaluate whether the genetic risk score adds appreciably to prediction afforded by the 
CHA2DS2-VASc score47 or individual stroke risk factors. Future studies are warranted to 
determine whether genetic risk adds additional information to other clinical and biomarker 
factors related to AF and stroke. Fourth, our genetic risk models were comprised of common 
SNPs genotyped in the HapMap reference populations,48 many of which are likely tag-SNPs 
and serve as proxies for true causal variation. Through the use of larger sample sizes and 
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newer techniques to comprehensively assess genomic variation, such as whole genome 
sequencing, we anticipate better power to identify causal variants underlying AF in the future. 
Inclusion of causal variants in genetic risk scores may improve the specificity of the models. 
Fifth, the genetic predictors of prevalent stroke may not be identical to those of incident stroke 
due to potential survival biases. Therefore, the clinical utility of AF genetic risk factors for 
identifying individuals at risk for incident stroke merits future study. 
 
Conclusions 
We observed that comprehensive AF genetic risk scores were associated with incident AF, 
exceeding effects of clinical risk factors, in individuals of European ancestry. We further 
observed that AF genetic risk is associated with both ischemic and cardioembolic stroke after 
adjustment for age and sex, even among individuals with cardioembolic stroke without 
established AF. Our findings underscore the polygenic nature of AF and the independent value 
of genetic information beyond clinical risk factors for the identification of individuals at risk for 
AF. However, although genetic risk scores are highly associated with AF, genetic information 
currently affords small improvements in discrimination of AF risk, and therefore does not yet 
need to be incorporated into routine clinical decision-making. Future clinical trials are necessary 
to rigorously assess whether AF genetic risk is an effective clinical marker of cardioembolic 
stroke etiology, and can identify individuals with subclinical AF. 
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FIGURE LEGENDS 
 
Figure 1. Pooled 5-year relative hazard of incident atrial fibrillation among individuals in the 
highest quartile of AF genetic risk relative to those in the lowest quartile. 
 
SNPs included in scores were derived using different thresholds of association between each 
SNP and atrial fibrillation in an earlier, independent study.15 
 
 
Figure 2. Risk of cardioembolic stroke in MGH-GASROS according to atrial fibrillation genetic 
risk.  
 
Odds ratios for cardioembolic stroke in relation to atrial fibrillation genetic risk scores among 
cardioembolic stroke cases and 3,028 controls. Blue histograms show distributions of genetic 
risk scores among cases and controls. Black dots indicate odds ratios for stroke for each 
quartile of genetic risk scores (bars indicate 95% confidence intervals). For panels A-C, genetic 
risk scores were based on 45 (A), 127 (B), and 701 (C) SNPs among 202 cardioembolic stroke 
cases (including 70 with known AF) and controls. For panels D-F, genetic risk scores were 
based 45 (D), 127 (E), and 701 (F) SNPs among 152 cardioembolic stroke cases (none with 
known AF) and controls. SNP totals may not equal those used in the incident atrial fibrillation 
analysis since some SNPs were unavailable in MGH-GASROS, in which case proxies were 
used when available (Supplemental Table 1).
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Table 1. Characteristics of participants included in analyses of incident atrial fibrillation. 
 MDCS MESA PREVEND PROSPER* BioVU 
No. total 8,226 2,451 1,624 5,212 1,388 
No. incident AF 190 76 34 503 229 
Age, years 59±7 63±10 58±8 75±3 60±11 
Women 4,275 (52) 1,321 (52) 770 (47) 2,716 (52) 678 (49) 
Height, cm 169±9 169±10 172±9 165±9 171±11 
Weight, kg 75±14 79±16 80±14 73±13 86±22 
Systolic blood pressure, mmHg 145±20 124±20 135±21 155±22 131±20 
Diastolic blood pressure, mmHg 87±10 75±10 77±10 84±11 75±30 
History of smoking 2,513 (31) 1,401 (55) 671 (41) 1,388 (27) 619 (45) 
Antihypertensive medication 1,799 (22) 840 (33) 362 (22) 3,854 (74) 1,339 (96) 
History of diabetes 542 (7) 151 (6) 98 (6) 540 (10) 359 (26) 
History of heart failure 39 (0.5) 52 (2) 4 (0.2) NA 161 (12) 
History of myocardial infarction 487 (9) 63 (3) 71 (4) 697 (13) 284 (20) 
Data presented as mean ± standard deviation, or No. (%) 
*Maximum follow-up in PROSPER was 4 years. 
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Table 2. Characteristics of participants of European ancestry included in analyses of ischemic 
stroke from MGH-GASROS and referents. 
 Cases Referents 
N 509 3,028 
Age, years 66.9 ± 14.4 42.3 ± 7.8 
Women 214 (24.2) 732 (42.0) 
Atrial fibrillation 87 (17) – 
Data presented as mean ± standard deviation, or No. (%) 
Stroke etiologic subtype: cardioembolic (n=202, 39%), large artery (n=114, 22%), small vessel / 
lacunar (n=62, 12%), other (n=124, 24%), undetermined (n=7, 1%).  
P for comparison of age and sex between cases and controls <0.001. 
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Figure 1. 
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Figure 2.  
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DESCRIPTIONS OF PARTICIPATING STUDIES 
 
Malmö Diet and Cancer Study (MDCS) 
MDCS is a community-based prospective epidemiologic cohort of middle-aged individuals from 
Southern Sweden.1 In total, 30,447 subjects attended a baseline exam in 1991-1996, when they 
filled out a questionnaire and underwent anthropometric and blood pressure measurements. 
Hypertension was defined as self-reported use of antihypertensive medications or measured 
blood pressure ≥140/90 mmHg. Prevalent or incident cases of atrial fibrillation (AF), heart failure 
and ischemic heart disease were ascertained from nation-wide hospital registers with high 
validity as described previously.2 Prevalent or incident diabetes was ascertained from a variety 
of regional and nationwide registers as described previously.3 Genome-wide genotyping of 
single nucleotide variants was performed using the Illumina Human Omni Express Exome 
BeadChip kit. Genotyping was performed in a nested case-cohort design, including a random 
subset of 5248 subjects and 3098 cases with incident coronary disease or stroke. Imputation 
was performed to genotypes in the 1000 Genomes Project phase 1 using IMPUTE.4 Analyses 
were performed using SAS version 9.3 for Windows (SAS institute, Cary, NC). 
 
Multi-Ethnic Study of Atherosclerosis (MESA)  
MESA is a community-based sample of 6,814 men and women without symptomatic 
cardiovascular disease aged 45-84 years (38% white; 28% African American; 22% Hispanic; 
and 12% Asian -- mainly of Chinese descent).5 Participants were recruited during 2000-2002 
from 6 field centers across the U.S. (at Wake Forest University; Columbia University; Johns 
Hopkins University; the University of Minnesota; Northwestern University, and the University of 
California – Los Angeles). All underwent anthropometric measurement and extensive evaluation 
by questionnaires at baseline, followed by 4 subsequent examinations at intervals of 
approximately 2-4 years. Current AF at baseline was an exclusion criterion. Follow-up phone 
calls to study participants (every 9-12 months) were used to identify all hospitalizations. Medical 
records, including discharge diagnoses, were obtained for each hospitalization. Incident AF was 
defined by International Classification of Disease codes 427.31 or 427.32 (9th revision). In 
addition, new diagnoses of AF were identified at follow-up by the presence of AF or atrial flutter 
on a study ECG at Exam 5 (approximately 10 years after baseline). Age and sex were self-
reported. Further information can be found at: 
http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000209.v13.p3 
 
European ancestry participants were genotyped on the Affymetrix Genome-Wide Human SNP 
Array 6.0 (Affymetrix, Santa Clara, CA) at the Affymetrix Research Services Lab. Plate-based 
genotype calling was with Birdseed v2. Additional genotypes were imputed to the 1000 
Genomes Phase I integrated variant set (NCBI build 37/hg19) separately in each ethnic group, 
by use of the IMPUTE2 program.4 Data freezes from 23 November 2010 (low-coverage whole-
genome) and 21 May 2011 (high-coverage exome), phased haplotypes released March 2012 
(v3), and phased haplotypes for 1,092 individuals and 39+ million variants were used. Analyses 
were performed using ProbABEL software.6 
 
PROspective Study of Pravastatin in the Elderly at Risk (PROSPER)  
PROSPER was a prospective multicenter randomized placebo-controlled trial to assess whether 
treatment with pravastatin diminishes the risk of major vascular events in the elderly.7 Between 
December 1997 and May 1999, subjects were screened and enrolled in Scotland (Glasgow), 
Ireland (Cork), and the Netherlands (Leiden). Men and women aged 70-82 years were recruited 
if they had pre-existing vascular disease or increased risk of such disease because of smoking, 
hypertension, or diabetes. A total of 5,804 subjects were randomly assigned to pravastatin or 
placebo. A large number of prospective tests were performed including BioBank tests and 
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cognitive function measurements. New diagnoses were identified by self-report or a physician 
diagnosis of AF, or by the presence of AF or atrial flutter on a study ECG done annually and at 
study run-out or at the time of an adverse event. Genome-wide genotyping was performed in 
the sequential PHASE project with the use of the Illumina 660K BeadChip in 5,763 subjects in 
whom DNA was available for genotyping. After QC exclusions (call rate <95%) 5,244 subjects 
and 557,192 SNPs were left for analysis, including 507 individuals with incident AF. These 
SNPs were imputed to 2.5 million SNPs based on the HapMap build 36 with MACH imputation 
software.8 Analyses were performed using Plink 1.079 and IBM SPSS statistics version 20. 
 
Prevention of Renal and Vascular Endstage Disease (PREVEND)  
The PREVEND cohort study was founded in 1997, and is an ongoing community-based cohort 
study including 8592 inhabitants of the city of Groningen, The Netherlands.10 PREVEND is 
investigating the natural course of microalbuminaria and its relation to renal and cardiovascular 
disease. Details of the protocol, AF ascertainment and covariate definitions have been 
described elsewhere (www.prevend.org). AF was ascertained if either atrial flutter or AF was 
present on a 12-lead ECG obtained at one of the three PREVEND follow-up visits, or at an 
outpatient visit or hospital admission in the two hospitals in the city of Groningen (University 
Medical Center Groningen and Martini Hospital). Systolic and diastolic blood pressures were 
calculated as the mean of the last two measurements of the two visits, using an automatic GE 
Dinamap XL Model 9300 series device. Hypertension was defined as systolic blood pressure 
>140 mmHg, diastolic blood pressure >90 mmHg, or use of antihypertensive drugs. Use of 
antihypertensive drugs was based on available information from the pharmacy prescription 
database. Type 2 diabetes was defined as a fasting plasma glucose >7.0 mmol/L (126 mg/dL), 
a nonfasting plasma glucose >11.1 mmol/L, or use of anti-diabetic drugs. Smoking was defined 
as any smoking within the last five years. History of myocardial infarction or stroke was defined 
as participant-reported hospitalization for at least 3 days as a result of this condition. A 
committee of heart failure experts adjudicated all participants with heart failure at baseline 
according to previously published criteria. Genotyping was performed using the Illumina 
CytoSNP12v2 array. Genotype calling was performed using GenomeStudio, and imputation was 
performed using Beagle11 with the HapMap release 22 CEU referent panel. Analyses were 
performed with Plink v1.079 and R.12  
 
Vanderbilt DNA Bio-bank (BioVU) 
Subjects were included from the Vanderbilt DNA Bio-bank (BioVU), for which a description of 
methods has been published.13-16 Inclusion criteria for patients selected from BioVU include age 
≥40 years, self-identified European or African American race, and no known previous history of 
AF as of December 2005. Patients with an ICD-9 code or CPT code for heart transplant were 
also excluded. Additionally, patients must have had at least three visits to the Vanderbilt Internal 
Medicine clinic within a 24-month period to ensure adequate follow-up for ascertainment of 
incident AF. Ascertainment of incident AF was achieved with a previously validated algorithm 
which uses natural language processing of cardiologist-interpreted ECG impressions and billing 
codes, with a positive predictive value of >95%.13 Patients with preexisting ICD-9 codes for AF 
or mention of AF in ECG interpretations or in the structured problem lists were excluded. Sex, 
race, age, weight, height, body mass index, and systolic and diastolic blood pressure were 
directly extracted from structured fields in the BioVU. History of myocardial infarction, heart 
failure, and diabetes mellitus were determined by using ICD-9 codes incorporating laboratory 
values and medication records. Treatment for hypertension was assessed using a previously 
validated algorithm incorporating medication records. This algorithm was previously shown to 
have a sensitivity and positive predictive value of 88% and 93%, respectively.14,15 PR interval 
and left ventricular hypertrophy were obtained from outpatient ECG reports. Current smoking 
status was determined by using an existing algorithm with a positive predictive value of 93% in 
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Vanderbilt medical records. AF susceptibility SNPs were available within BioVU based on one of 
two GWAS chips (Illumina OMNI-Quad or Illumina HumanOmni5-Quad). Analyses were 
performed using PLINK v1.07.9 
 
Massachusetts General Hospital Genes Associated with Stroke Risk and Outcomes 
Study (MGH-GASROS) 
MGH-GASROS enrolled ischemic stroke subjects as part of a single-center prospective cohort 
study of consecutive patients with ischemic stroke aged ≥18 years admitted to the 
Massachusetts General Hospital Stroke Unit (Boston, MA, U.S.A.) between 2000 and 2011 after 
presenting to the emergency department within 24 hours of symptom onset.17-19 Ischemic stroke 
was defined as a clinical syndrome of any duration associated with a radiographically proven 
acute infarct consistent with a vascular pattern of involvement and without radiographic 
evidence of a demyelinating or neoplastic disease or other structural disease, including 
vasculitis, subacute bacterial endocarditis, vasospasm due to subarachnoid hemorrhage or 
cocaine abuse, or primary intracerebral hemorrhage. Diagnosis of acute cerebral ischemia was 
confirmed for all subjects in the present study by admission diffusion weighted imaging 
completed within 48 hours after symptom onset. Vascular and critical care neurologists 
subtyped ischemic strokes by systematic medical record review using the TOAST criteria.20 
Referents were matched to cases on the basis of age, sex and race/ethnicity and drawn from 
stroke-free individuals who received care at primary care practices within Massachusetts 
General Hospital or from the Myocardial Infarction Genetics Consortium study who did not have 
a history of myocardial infarction.21 All cases included in this analysis were genotyped on the 
Affymetrix 6.0 array. Genotypes were imputed with the 1000 genomes reference panel-imputed 
dataset using MACH 1.0.8 Analyses were performed using PLINK9 and R v3.2.3.12  
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Supplemental Table 1. SNPs used to construct atrial fibrillation genetic risk scores. 
SNP 
Risk 
Allele 
Risk Allele 
Weight 
P-value, prior AFGen 
analysis 
Proxy SNP for 
stroke 
analysis 
Proxy Risk 
Allele for 
stroke 
analysis 
Proxy Risk 
Allele Weight 
for stroke 
analysis 
Proxy P-value, 
prior AFGen 
analysis 
rs999790 G 0.0709 0.00042 Same – – 
 rs9997270 C 0.2009 0.0009509 Same – – 
 rs9995522 A 0.1631 0.0003767 Same – – 
 rs996831 A 0.077 0.0005751 Same – – 
 rs9967820 G 0.1263 4.51E-06 Same – – 
 rs9959337 T 0.0765 0.000182 Same – – 
 rs9952696 A 0.1151 0.0003895 Same – – 
 rs9950749 C 0.0778 0.0001595 Same – – 
 rs9945543 G 0.0892 6.93E-05 Same – – 
 rs9916520 C 0.0937 0.0005965 Same – – 
 rs988965 A 0.0884 0.0004757 Same – – 
 rs9857326 A 0.0864 3.86E-05 Same – – 
 rs9855666 G 0.078 0.0005965 Same – – 
 rs9842908 A 0.1248 0.000498 Same – – 
 rs9808055 G 0.2947 0.0008073 Same – – 
 rs972691 G 0.0733 0.0005745 Same – – 
 rs971215 A 0.0706 0.0003552 Same – – 
 rs967582 C 0.0742 0.0002823 Same – – 
 rs967417 A 0.0683 0.0005426 Same – – 
 rs966985 T 0.0939 0.0004213 Same – – 
 rs96501 T 0.0943 0.0004979 Same – – 
 rs964329 G 0.1455 0.0003223 Same – – 
 rs9641292 C 0.1145 0.0007157 Same – – 
 rs9612028 C 0.1013 0.00077 Same – – 
 rs9604978 G 0.115 0.0003395 Same – – 
 rs9597111 T 0.1419 0.000275 Same – – 
 rs9576962 T 0.1294 0.0006991 Same – – 
 rs9576555 A 0.0916 0.000114 Same – – 
 rs9537252 T 0.0728 0.0004041 Same – – 
 rs9537090 G 0.1604 6.27E-05 Same – – 
 rs9527662 T 0.0749 0.0004779 Same – – 
 rs9521715 T 0.0774 0.0008422 Same – – 
 rs9509908 T 0.0677 0.0007851 Same – – 
 rs9506441 A 0.2623 0.0001901 Same – – 
 rs9471552 G 0.0818 0.0007915 Same – – 
 rs947142 T 0.0699 0.000959 Same – – 
 rs943165 A 0.091 0.000233 Same – – 
 rs9408879 T 0.0721 0.0004965 Same – – 
 rs939046 A 0.0787 0.0006821 Same – – 
 rs9370893 C 0.0766 0.000605 Same – – 
 rs9367983 C 0.0876 0.0001479 Same – – 
 rs9357699 C 0.1352 0.0007776 Same – – 
 rs9326957 A 0.1534 0.0003096 Same – – 
 rs9324924 T 0.0876 0.0003213 Same – – 
 rs9305560 A 0.1737 5.77E-06 Same – – 
 rs9302230 T 0.075 0.000543 Same – – 
 rs9290226 C 0.1375 0.0004203 Same – – 
 rs9284844 G 0.1152 2.66E-05 Same – – 
 rs928462 T 0.0928 0.0009445 Same – – 
 rs9283513 A 0.0798 0.0003553 Same – – 
 rs9267992 G 0.1108 3.97E-05 Same – – 
 rs926198 T 0.0775 0.0002435 Same – – 
 rs907687 T 0.0765 0.0001474 Same – – 
 rs905938 C 0.0786 0.0006768 Same – – 
 rs903369 C 0.0686 0.0005633 Same – – 
 rs894915 T 0.0679 0.0008269 Same – – 
 rs894486 T 0.0656 0.0009246 Same – – 
 rs892779 T 0.1117 0.000555 Same – – 
 rs882272 G 0.0658 0.0009908 Same – – 
 rs879596 A 0.186 0.0003045 Same – – 
 rs867039 T 0.0938 0.0008669 Same – – 
 rs8601 T 0.0904 0.0002579 Same – – 
 rs851340 T 0.0805 0.0006082 Same – – 
 rs833632 A 0.0951 9.49E-05 Same – – 
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rs831430 T 0.0929 0.0004522 Same – – 
 rs831157 T 0.1531 0.0005754 Same – – 
 rs8190612 T 0.1109 0.0003253 Same – – 
 rs818539 T 0.1179 0.0002205 Same – – 
 rs8110127 G 0.0987 0.0005929 Same – – 
 rs8108108 C 0.0744 0.0003449 Same – – 
 rs8100255 T 0.0864 0.0004184 Same – – 
 rs8097177 C 0.078 0.0001023 Same – – 
 rs8055406 G 0.1078 0.0002013 Same – – 
 rs804877 G 0.128 0.0002775 Same – – 
 rs8040533 G 0.1512 1.18E-08 Same – – 
 rs8031860 T 0.0823 0.0007623 Same – – 
 rs8018219 C 0.0984 0.0008182 Same – – 
 rs800683 T 0.1615 0.0003792 Same – – 
 rs7994886 C 0.0744 0.0004458 Same – – 
 rs7989027 A 0.0845 0.0002692 Same – – 
 rs7987944 C 0.0862 4.88E-05 Same – – 
 rs7943633 C 0.1442 0.0001747 Same – – 
 rs7937519 T 0.1224 0.0006523 None – – 
 rs7922194 A 0.2135 0.0007589 Same – – 
 rs7915465 T 0.1263 0.0004347 Same – – 
 rs7900898 A 0.1333 0.0006515 Same – – 
 rs7872739 C 0.0984 0.0005469 Same – – 
 rs785437 G 0.0793 0.0008837 Same – – 
 rs7835679 C 0.1794 2.24E-05 Same – – 
 rs7816647 T 0.0847 0.0006835 Same – – 
 rs7816571 C 0.0694 0.0008364 Same – – 
 rs778308 C 0.0881 0.0008865 Same – – 
 rs7781814 C 0.1015 0.0004185 Same – – 
 rs7773151 C 0.0799 0.0007361 Same – – 
 rs7763785 G 0.09 0.0008738 Same – – 
 rs7753843 T 0.088 3.00E-05 Same – – 
 rs7740137 A 0.1279 0.0001804 Same – – 
 rs7736938 G 0.1074 0.0001888 Same – – 
 rs768347 T 0.1077 1.35E-05 Same – – 
 rs7682872 G 0.0877 2.77E-05 Same – – 
 rs7653939 A 0.0678 0.0009816 Same – – 
 rs765039 G 0.0715 0.0004416 Same – – 
 rs7650184 C 0.0789 0.0002269 Same – – 
 rs7638909 T 0.0992 9.33E-05 Same – – 
 rs7635053 A 0.0721 0.0006369 Same – – 
 rs7635004 A 0.1087 0.000617 Same – – 
 rs762919 G 0.088 0.0004319 Same – – 
 rs7608839 T 0.0942 0.0001427 Same – – 
 rs7600577 A 0.0984 0.0008042 Same – – 
 rs7591917 A 0.1438 0.0004477 Same – – 
 rs7568221 G 0.0754 0.0007074 Same – – 
 rs7556675 C 0.0747 0.0007203 Same – – 
 rs7553796 A 0.0866 1.40E-05 Same – – 
 rs7537634 A 0.1566 0.000959 Same – – 
 rs7506639 T 0.0748 0.0004676 Same – – 
 rs7434264 G 0.0844 0.0004807 Same – – 
 rs7427154 G 0.1322 0.0003427 Same – – 
 rs740854 A 0.1463 0.0002195 Same – – 
 rs739455 G 0.2157 8.41E-05 Same – – 
 rs737558 T 0.0722 0.0009392 Same – – 
 rs7359646 T 0.0734 0.0004197 Same – – 
 rs7330782 A 0.0718 0.0008629 Same – – 
 rs731341 G 0.0863 0.0002601 Same – – 
 rs7295704 T 0.0974 4.85E-05 Same – – 
 rs7285376 G 0.1149 0.0002265 Same – – 
 rs727716 G 0.1004 0.0009923 Same – – 
 rs727037 A 0.0677 0.0007911 Same – – 
 rs7270354 A 0.1069 0.0002324 Same – – 
 rs7269069 A 0.1222 0.0006223 Same – – 
 rs7246182 C 0.0861 0.0001722 Same – – 
 rs7235339 G 0.0758 0.000745 Same – – 
 rs723370 G 0.1166 8.75E-05 Same – – 
 rs7227127 A 0.1062 0.000611 Same – – 
 rs7182401 T 0.074 0.0009984 Same – – 
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rs7179371 T 0.0771 0.0001613 Same – – 
 rs7171648 C 0.1597 6.03E-07 Same – – 
 rs716226 A 0.0962 0.0002127 Same – – 
 rs7160770 T 0.0818 4.98E-05 Same – – 
 rs715888 G 0.0779 0.0004704 Same – – 
 rs7154452 T 0.0894 8.67E-05 Same – – 
 rs7149330 G 0.0918 0.0008075 Same – – 
 rs7143846 A 0.1826 0.00014 Same – – 
 rs7068070 A 0.0956 7.00E-05 Same – – 
 rs7046258 C 0.1113 7.46E-05 Same – – 
 rs7035855 A 0.1106 0.0001165 Same – – 
 rs698809 T 0.0983 8.88E-05 Same – – 
 rs6978506 T 0.0813 0.0008759 Same – – 
 rs6968408 C 0.1518 1.82E-05 Same – – 
 rs696815 A 0.075 0.0003945 Same – – 
 rs6960162 G 0.0785 0.0003706 Same – – 
 rs6937605 C 0.0993 0.0002454 Same – – 
 rs6889305 C 0.0936 0.0003172 Same – – 
 rs6884185 C 0.092 4.47E-05 Same – – 
 rs6882776 G 0.0981 3.72E-05 Same – – 
 rs6843738 A 0.0808 9.28E-05 Same – – 
 rs6838973 C 0.19 8.83E-20 Same – – 
 rs6817105 C 0.493 1.79E-74 Same – – 
 rs6802120 C 0.0959 0.0005904 Same – – 
 rs6799133 A 0.0693 0.0009501 Same – – 
 rs6783573 G 0.0753 0.0003241 Same – – 
 rs6773303 A 0.1001 0.0007051 Same – – 
 rs6771278 T 0.0724 0.0004924 Same – – 
 rs6760338 C 0.261 9.28E-05 Same – – 
 rs6756513 G 0.0871 0.0001274 Same – – 
 rs6749773 A 0.0807 4.88E-05 Same – – 
 rs6740528 A 0.1255 0.0001158 Same – – 
 rs6731358 A 0.085 6.46E-05 Same – – 
 rs6706362 G 0.069 0.0005745 Same – – 
 rs6706171 C 0.0705 0.0004507 None – – 
 rs670217 G 0.1002 0.0003183 Same – – 
 rs6701767 C 0.0885 0.0009411 Same – – 
 rs6688119 T 0.0738 0.0009302 Same – – 
 rs6684191 A 0.08 0.0001631 Same – – 
 rs6669826 T 0.0854 0.0008446 Same – – 
 rs6669689 A 0.0835 0.0001496 Same – – 
 rs6666258 C 0.1665 1.99E-14 Same – – 
 rs6601786 T 0.0753 0.0004841 Same – – 
 rs6599254 G 0.0981 1.32E-06 Same – – 
 rs6585467 G 0.0692 0.0008571 Same – – 
 rs6580289 C 0.0692 0.0004702 Same – – 
 rs6575317 A 0.0779 0.0001291 Same – – 
 rs6544745 C 0.166 0.0003509 Same – – 
 rs6540690 C 0.1124 3.60E-05 Same – – 
 rs6505893 C 0.155 9.84E-05 Same – – 
 rs6492689 G 0.0722 0.0006586 Same – – 
 rs6480771 T 0.081 5.94E-05 Same – – 
 rs6479643 C 0.0765 0.0007205 Same – – 
 rs6479562 A 0.0898 6.36E-06 Same – – 
 rs6464716 A 0.0756 0.0006204 Same – – 
 rs6463968 C 0.0992 0.0006955 Same – – 
 rs6455760 A 0.1092 0.0001525 Same – – 
 rs6428323 C 0.0801 0.0004511 Same – – 
 rs6426872 A 0.108 3.53E-05 Same – – 
 rs6151704 T 0.0664 0.0008943 Same – – 
 rs6086773 T 0.1121 0.0005113 Same – – 
 rs6062468 C 0.0926 4.69E-05 None – – 
 rs6027956 T 0.0667 0.0009729 Same – – 
 rs6025056 G 0.1221 0.0002237 Same – – 
 rs6021268 T 0.1338 0.00071 Same – – 
 rs582679 C 0.0934 0.0001896 Same – – 
 rs574344 A 0.1272 0.0008018 Same – – 
 rs570557 T 0.1064 0.0007349 Same – – 
 rs549793 T 0.0859 0.0007425 Same – – 
 rs542214 A 0.0873 0.0002498 Same – – 
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rs526428 T 0.1318 0.0002971 Same – – 
 rs525476 T 0.073 0.0006471 Same – – 
 rs519862 A 0.0956 0.0008055 Same – – 
 rs5021390 A 0.0876 0.0004046 Same – – 
 rs4999127 A 0.1244 4.78E-05 Same – – 
 rs4976490 C 0.0687 0.0007676 Same – – 
 rs4972960 C 0.0952 0.0009473 Same – – 
 rs4963646 G 0.0804 0.0004239 Same – – 
 rs495558 T 0.0732 0.0003349 Same – – 
 rs4954876 C 0.0693 0.00054 Same – – 
 rs4953359 T 0.069 0.0004393 Same – – 
 rs4953340 C 0.0942 5.13E-05 Same – – 
 rs4948721 G 0.0752 0.0005691 Same – – 
 rs4948002 A 0.099 0.0009979 Same – – 
 rs4935117 T 0.1253 0.000646 Same – – 
 rs4935020 C 0.0678 0.0007237 Same – – 
 rs4934284 G 0.116 0.0009329 Same – – 
 rs4920085 A 0.1449 0.0002021 Same – – 
 rs4919621 A 0.0707 0.0004468 Same – – 
 rs4918068 T 0.1067 0.0007752 Same – – 
 rs4906630 G 0.1009 0.0004169 Same – – 
 rs4905933 C 0.0661 0.0009254 Same – – 
 rs4905434 G 0.0966 0.0003021 Same – – 
 rs4885350 A 0.1571 0.0002617 Same – – 
 rs4884651 G 0.0693 0.0009082 Same – – 
 rs4883463 T 0.0931 0.0007186 Same – – 
 rs4876578 A 0.1619 0.0004301 Same – – 
 rs4871397 G 0.1787 4.79E-05 Same – – 
 rs4871385 C 0.0821 0.0009759 Same – – 
 rs4833233 G 0.0695 0.0003512 Same – – 
 rs4824051 C 0.101 4.63E-05 None – – 
 rs4820556 G 0.0998 0.0005384 Same – – 
 rs4817760 C 0.0871 0.0002949 Same – – 
 rs478438 A 0.129 0.0001138 Same – – 
 rs4771852 T 0.1153 0.0008374 Same – – 
 rs4751029 A 0.1431 0.0005413 Same – – 
 rs4735076 C 0.1298 0.0005567 Same – – 
 rs4733547 T 0.0944 0.0003332 Same – – 
 rs4692402 G 0.0906 0.0003912 Same – – 
 rs4686419 T 0.0741 0.0009283 Same – – 
 rs4663039 A 0.1226 0.0005702 None – – 
 rs4636640 A 0.0807 0.0007712 Same – – 
 rs4625692 A 0.111 8.00E-06 Same – – 
 rs4624886 A 0.0971 0.000315 Same – – 
 rs4595097 T 0.0841 0.0005249 Same – – 
 rs4543168 G 0.1012 0.0007033 Same – – 
 rs4540309 C 0.0985 0.000629 Same – – 
 rs4530555 T 0.101 0.0001293 Same – – 
 rs4501708 T 0.0845 0.0007866 Same – – 
 rs445 C 0.1157 0.0008584 Same – – 
 rs4429865 T 0.078 0.0004962 Same – – 
 rs4403607 T 0.1034 0.0002978 Same – – 
 rs4401604 A 0.0971 0.0003168 Same – – 
 rs4384031 T 0.0743 0.0003445 Same – – 
 rs4358298 G 0.0761 0.0006723 Same – – 
 rs4321363 T 0.1296 0.0005855 Same – – 
 rs4301399 T 0.1654 0.0001795 Same – – 
 rs4246224 G 0.1485 2.23E-07 Same – – 
 rs4243595 T 0.0664 0.0009938 Same – – 
 rs4238314 A 0.0841 2.72E-05 Same – – 
 rs4235054 A 0.0723 0.0003747 Same – – 
 rs4234206 T 0.0766 0.0008328 Same – – 
 rs416532 T 0.0932 5.38E-06 Same – – 
 rs414871 C 0.101 0.0003497 Same – – 
 rs4131707 C 0.0971 0.0003903 Same – – 
 rs413113 G 0.0869 0.0008832 Same – – 
 rs413089 C 0.0971 0.0005648 Same – – 
 rs4124163 A 0.2757 9.12E-07 Same – – 
 rs4112823 C 0.1083 0.0004601 Same – – 
 rs4032974 C 0.1809 2.57E-08 Same – – 
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rs3922843 A 0.099 9.65E-06 Same – – 
 rs3917686 T 0.116 0.0008529 Same – – 
 rs3908748 A 0.3312 0.0005776 None – – 
 rs3866823 A 0.114 3.42E-08 Same – – 
 rs3855819 C 0.0955 0.0005116 Same – – 
 rs3853444 T 0.1541 8.47E-10 Same – – 
 rs3848421 A 0.0681 0.0009705 Same – – 
 rs3846687 T 0.0697 0.0007337 Same – – 
 rs3826046 G 0.1454 0.0004443 Same – – 
 rs3824359 C 0.1121 9.25E-05 Same – – 
 rs3821120 C 0.0728 0.0008406 Same – – 
 rs3807989 G 0.1308 9.60E-11 Same – – 
 rs3803833 G 0.0893 0.0006764 Same – – 
 rs3790999 A 0.0745 0.000441 Same – – 
 rs378892 C 0.084 0.0001332 Same – – 
 rs3782464 C 0.0886 3.31E-05 Same – – 
 rs3780190 G 0.1 6.27E-06 Same – – 
 rs3772584 C 0.2015 0.0009454 Same – – 
 rs3765618 G 0.1622 0.0007342 Same – – 
 rs3748608 A 0.0791 0.0004114 Same – – 
 rs3739287 C 0.141 8.29E-05 Same – – 
 rs3731399 T 0.1203 0.0004015 Same – – 
 rs364926 T 0.0741 0.0008743 Same – – 
 rs363895 A 0.0678 0.0008601 Same – – 
 rs361540 A 0.0745 0.0003824 Same – – 
 rs352193 G 0.1143 0.0007381 Same – – 
 rs352101 T 0.069 0.0007602 Same – – 
 rs345523 T 0.0981 0.0001086 Same – – 
 rs3427 T 0.0786 0.0006064 Same – – 
 rs34022 C 0.0753 0.0003105 Same – – 
 rs337711 T 0.0673 0.0008797 Same – – 
 rs325609 G 0.1603 5.39E-05 Same – – 
 rs325410 C 0.0802 0.0007824 rs170522 T 0.0789 0.0008017 
rs31864 G 0.0721 0.0002855 Same – – 
 rs3135005 A 0.0982 0.0003759 Same – – 
 rs3117572 A 0.0886 0.0006333 Same – – 
 rs3099794 C 0.0697 0.0006863 Same – – 
 rs306290 C 0.0737 0.0005804 Same – – 
 rs304586 C 0.07 0.0005192 Same – – 
 rs2989724 T 0.0789 0.0003493 Same – – 
 rs2980785 G 0.1288 0.0001589 Same – – 
 rs2975424 C 0.0905 0.0003967 Same – – 
 rs2973501 G 0.0727 0.0008289 Same – – 
 rs297005 C 0.0759 0.0003989 Same – – 
 rs295136 G 0.0781 0.0001581 Same – – 
 rs2941405 C 0.0998 4.79E-05 Same – – 
 rs2922431 T 0.0728 0.0009478 Same – – 
 rs287927 A 0.0802 0.0005006 Same – – 
 rs2876520 C 0.0797 9.99E-05 Same – – 
 rs2872583 G 0.1159 0.0009051 Same – – 
 rs2838561 A 0.098 0.0001766 Same – – 
 rs2836546 A 0.0704 0.0007485 Same – – 
 rs2834618 T 0.1269 0.0002241 Same – – 
 rs2833575 G 0.0751 0.0004759 Same – – 
 rs2833272 T 0.0679 0.0006061 Same – – 
 rs283077 T 0.0728 0.0002076 Same – – 
 rs2827784 T 0.067 0.0009029 Same – – 
 rs2824430 T 0.1196 0.0004646 Same – – 
 rs2816146 C 0.1048 0.0003766 Same – – 
 rs2813865 G 0.0964 0.0001445 Same – – 
 rs276857 G 0.1452 1.00E-05 Same – – 
 rs2738627 A 0.094 0.0002961 Same – – 
 rs2729553 A 0.0815 0.0001028 Same – – 
 rs2724028 A 0.0789 0.0009407 Same – – 
 rs2723065 A 0.0996 9.71E-07 Same – – 
 rs2705081 C 0.1269 0.0008007 Same – – 
 rs2685217 T 0.1066 2.58E-05 Same – – 
 rs2681581 A 0.1649 0.0005694 Same – – 
 rs2680702 G 0.0718 0.0005217 Same – – 
 rs2670005 T 0.085 0.0001239 Same – – 
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rs2668132 C 0.0724 0.0003518 Same – – 
 rs2656924 C 0.1142 0.0009033 Same – – 
 rs2648034 A 0.0726 0.0002611 Same – – 
 rs2642444 G 0.0893 0.000932 Same – – 
 rs2620805 A 0.0768 0.0009405 Same – – 
 rs260105 G 0.0971 0.0002333 Same – – 
 rs2595102 G 0.1529 3.08E-13 Same – – 
 rs2595098 T 0.2634 0.0005396 Same – – 
 rs2586047 A 0.0735 0.0003488 Same – – 
 rs2585844 C 0.0907 0.0001395 Same – – 
 rs2570514 T 0.0791 0.0004178 Same – – 
 rs256241 A 0.1059 0.000163 Same – – 
 rs2543593 C 0.0753 0.0006126 Same – – 
 rs2537730 C 0.0954 0.0002322 Same – – 
 rs2536929 A 0.0958 0.0001397 Same – – 
 rs2532144 T 0.0917 2.97E-05 rs2532170 A 0.0812 0.0001016 
rs2487030 C 0.0831 0.0009809 Same – – 
 rs2449442 G 0.0949 0.0001377 Same – – 
 rs2431626 C 0.0705 0.0009197 Same – – 
 rs2427653 A 0.078 0.0006965 Same – – 
 rs2415062 A 0.0734 0.0005245 Same – – 
 rs239731 C 0.1077 0.0001126 Same – – 
 rs2377868 T 0.0856 0.0008476 Same – – 
 rs2372523 A 0.0794 0.0003789 Same – – 
 rs2358891 G 0.102 1.46E-05 Same – – 
 rs2356121 G 0.0695 0.0009046 Same – – 
 rs233297 C 0.1466 0.000485 Same – – 
 rs2332010 A 0.1222 0.0007228 Same – – 
 rs2329198 A 0.0647 0.0009603 Same – – 
 rs2323453 A 0.0681 0.000886 Same – – 
 rs2312586 C 0.0865 0.0003701 Same – – 
 rs2305826 T 0.0682 0.0007273 Same – – 
 rs2305398 G 0.097 4.21E-06 Same – – 
 rs2304921 C 0.1542 0.0003267 Same – – 
 rs2301556 A 0.1205 0.0005997 Same – – 
 rs2300255 G 0.1334 0.0008987 Same – – 
 rs2293793 T 0.0731 0.0006585 Same – – 
 rs2287933 C 0.1405 0.0001837 Same – – 
 rs2285655 T 0.1572 0.0007498 Same – – 
 rs2283229 A 0.1029 0.0003326 Same – – 
 rs2278008 C 0.0807 0.0006333 Same – – 
 rs2270307 G 0.0737 0.0008804 Same – – 
 rs2269252 T 0.0919 0.0002533 Same – – 
 rs2256154 C 0.0781 0.0001369 Same – – 
 rs2256109 C 0.0689 0.0009157 Same – – 
 rs2255648 G 0.0742 0.000235 Same – – 
 rs2249965 A 0.1067 5.67E-07 Same – – 
 rs2239650 A 0.1473 0.0004591 Same – – 
 rs223484 A 0.0658 0.0009278 Same – – 
 rs2204224 T 0.1721 3.58E-05 Same – – 
 rs2204037 A 0.0686 0.0006245 Same – – 
 rs2203298 G 0.1174 0.0008067 Same – – 
 rs2191502 C 0.099 0.0009714 Same – – 
 rs2179434 G 0.0766 0.0001084 Same – – 
 rs2166451 G 0.0784 0.0002175 Same – – 
 rs216495 G 0.0908 0.000135 Same – – 
 rs2145587 A 0.1037 2.01E-05 Same – – 
 rs2145274 A 0.1261 0.0005466 Same – – 
 rs2129531 G 0.0802 0.0008973 Same – – 
 rs2118254 C 0.0821 3.54E-05 Same – – 
 rs2106261 T 0.2119 3.21E-16 Same – – 
 rs2080859 C 0.1756 0.0002154 Same – – 
 rs2074897 A 0.0761 0.000427 Same – – 
 rs2070450 A 0.1534 0.0003574 Same – – 
 rs2070394 A 0.0708 0.000759 Same – – 
 rs2060915 C 0.0891 0.0001147 Same – – 
 rs20583 T 0.0773 0.0001107 Same – – 
 rs2049170 T 0.1249 0.000119 Same – – 
 rs2040862 T 0.1403 3.23E-08 Same – – 
 rs2038750 C 0.0743 0.0008719 Same – – 
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rs2033570 C 0.0846 4.29E-05 Same – – 
 rs2026943 A 0.0753 0.0005803 Same – – 
 rs2012056 A 0.0845 0.0009872 Same – – 
 rs2012 C 0.1066 5.90E-05 Same – – 
 rs2011708 T 0.0705 0.0008875 Same – – 
 rs1998713 C 0.0976 0.0009139 Same – – 
 rs1979325 G 0.0861 9.54E-05 Same – – 
 rs1956889 C 0.0856 0.0005242 Same – – 
 rs1930006 A 0.0712 0.0006367 Same – – 
 rs1927551 G 0.0968 0.0003716 Same – – 
 rs1924755 T 0.1071 0.0006807 Same – – 
 rs1912432 T 0.0755 0.0007791 Same – – 
 rs186385 A 0.1344 0.0006239 Same – – 
 rs1863244 C 0.0785 0.0001569 Same – – 
 rs1858810 A 0.0963 1.75E-06 Same – – 
 rs1845823 A 0.1637 0.0003139 Same – – 
 rs1829794 G 0.076 0.0009071 Same – – 
 rs1822010 T 0.1602 0.0004568 Same – – 
 rs1814331 T 0.1463 1.75E-05 Same – – 
 rs179141 G 0.0882 0.0007204 Same – – 
 rs17825517 G 0.2147 7.15E-05 Same – – 
 rs17782302 T 0.1042 0.0004657 Same – – 
 rs17763750 T 0.1151 0.0003792 Same – – 
 rs17714333 A 0.0689 0.0007347 Same – – 
 rs17688347 C 0.0727 0.0004262 Same – – 
 rs17656084 G 0.1936 0.0006964 Same – – 
 rs17644458 G 0.0862 6.51E-05 Same – – 
 rs17602834 C 0.0834 0.000105 Same – – 
 rs17588172 T 0.0961 3.59E-06 Same – – 
 rs17547641 A 0.0764 0.0009608 Same – – 
 rs17513835 T 0.1722 0.0004954 Same – – 
 rs17497040 T 0.1064 0.0003674 Same – – 
 rs17488597 T 0.1584 0.0001377 Same – – 
 rs17461036 T 0.1419 0.0006682 Same – – 
 rs1742424 A 0.1399 0.0002221 Same – – 
 rs17382780 T 0.1422 0.0008297 Same – – 
 rs17375901 T 0.2051 7.65E-07 Same – – 
 rs17367630 G 0.0771 0.0007701 Same – – 
 rs17360555 C 0.1009 0.0007306 Same – – 
 rs17353336 T 0.0685 0.0005781 Same – – 
 rs17318925 T 0.089 0.000694 Same – – 
 rs17314711 C 0.1674 0.000232 Same – – 
 rs17312183 C 0.1257 0.0008118 Same – – 
 rs17311216 C 0.1087 0.0009252 Same – – 
 rs17272614 C 0.0868 0.0006487 Same – – 
 rs17251567 C 0.0893 0.0005805 Same – – 
 rs17231256 A 0.1094 0.0002389 Same – – 
 rs17220640 C 0.1696 0.0004408 Same – – 
 rs17175458 G 0.0974 8.22E-05 Same – – 
 rs17153945 C 0.1328 0.0004457 Same – – 
 rs17150049 A 0.0916 6.74E-05 Same – – 
 rs1714520 C 0.0828 0.0006938 Same – – 
 rs17144562 T 0.1165 0.0002255 Same – – 
 rs17141635 A 0.1632 0.0009238 Same – – 
 rs17131865 T 0.1403 0.0009596 Same – – 
 rs17130025 A 0.1109 0.0004965 Same – – 
 rs17126643 G 0.1671 0.0003271 Same – – 
 rs17092243 C 0.087 0.0006306 Same – – 
 rs17083278 C 0.0988 0.0004775 Same – – 
 rs17077544 G 0.1475 6.80E-05 Same – – 
 rs17076 G 0.0885 0.0004944 Same – – 
 rs17073625 T 0.1234 0.0006776 Same – – 
 rs17066602 A 0.0696 0.0004673 Same – – 
 rs17066205 A 0.1317 0.0009994 Same – – 
 rs17059827 G 0.1432 0.000871 Same – – 
 rs17058126 C 0.189 0.0009206 Same – – 
 rs17014446 T 0.1476 0.0003945 Same – – 
 rs16994191 A 0.1268 0.0003505 Same – – 
 rs16991711 A 0.1246 0.000802 Same – – 
 rs16987853 C 0.1124 5.89E-05 rs11897611 T 0.1103 6.52E-05 
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rs16969763 A 0.2226 0.0005382 Same – – 
 rs16935005 A 0.1589 3.71E-05 Same – – 
 rs16931023 G 0.098 0.0001825 Same – – 
 rs169260 C 0.1635 0.0003675 Same – – 
 rs16890706 G 0.1106 0.0004265 Same – – 
 rs16866575 G 0.1207 0.0007645 Same – – 
 rs16839275 A 0.0705 0.000742 Same – – 
 rs16829334 A 0.153 0.0001607 Same – – 
 rs1649987 G 0.0923 0.0004631 Same – – 
 rs1642294 C 0.0989 0.0003718 Same – – 
 rs1628543 G 0.0742 0.0002296 Same – – 
 rs1615708 T 0.1038 0.0005336 Same – – 
 rs1609560 A 0.0887 0.0003465 Same – – 
 rs1602932 A 0.087 0.0001905 Same – – 
 rs1592418 G 0.0723 0.0006115 Same – – 
 rs1575738 C 0.1636 0.0009177 Same – – 
 rs1575017 A 0.1328 0.00083 Same – – 
 rs1573379 A 0.073 0.000623 Same – – 
 rs1567451 A 0.1044 0.0008447 Same – – 
 rs1560002 C 0.0781 0.0008729 Same – – 
 rs1547189 T 0.0928 0.0002198 Same – – 
 rs1543511 T 0.0686 0.0009882 Same – – 
 rs1539289 T 0.0672 0.0007177 Same – – 
 rs153675 T 0.0966 0.0001437 Same – – 
 rs1535507 T 0.0935 0.0009928 Same – – 
 rs1509798 G 0.1015 0.0004494 Same – – 
 rs1476221 A 0.1023 0.000242 Same – – 
 rs1469968 C 0.1418 1.52E-06 rs751664 A 0.0705 0.0005874 
rs1458041 A 0.0784 0.0007931 Same – – 
 rs1454934 T 0.0954 0.000418 Same – – 
 rs1421168 T 0.1592 0.0002344 Same – – 
 rs1416731 G 0.0885 0.0001145 Same – – 
 rs1396114 C 0.0897 0.0007521 Same – – 
 rs1381453 T 0.086 0.0002942 Same – – 
 rs1376803 T 0.0978 0.0002489 Same – – 
 rs137576 T 0.2537 0.0004097 Same – – 
 rs1375617 T 0.1387 0.0009448 Same – – 
 rs1369890 T 0.0777 0.000253 Same – – 
 rs136866 A 0.077 0.000605 Same – – 
 rs1366798 T 0.0692 0.0005711 Same – – 
 rs1366398 G 0.1169 0.000164 Same – – 
 rs1355846 G 0.0741 0.0003103 Same – – 
 rs1348388 T 0.0965 0.0007986 Same – – 
 rs1347832 A 0.0723 0.000998 Same – – 
 rs13439337 T 0.2294 3.34E-05 Same – – 
 rs13424875 A 0.0851 0.0005089 Same – – 
 rs134101 T 0.0853 0.000953 Same – – 
 rs13379000 T 0.3715 0.0006509 Same – – 
 rs13378344 C 0.0833 0.0007269 Same – – 
 rs13313289 C 0.1514 0.0009002 Same – – 
 rs13287050 T 0.0845 0.0003014 Same – – 
 rs13259395 G 0.207 3.53E-05 Same – – 
 rs13259235 C 0.0849 0.0007139 Same – – 
 rs13257090 C 0.0764 0.0001481 Same – – 
 rs13247344 A 0.0718 0.0009817 Same – – 
 rs13244286 A 0.173 0.000181 Same – – 
 rs13216675 T 0.0929 4.99E-05 Same – – 
 rs13213991 T 0.1305 0.0002955 Same – – 
 rs1320362 T 0.0754 0.0001197 Same – – 
 rs13173061 A 0.0684 0.0006922 Same – – 
 rs13169864 G 0.1183 4.49E-05 Same – – 
 rs13144278 G 0.1252 0.0003107 Same – – 
 rs13133886 A 0.0874 0.0004338 Same – – 
 rs13129710 C 0.079 0.0004948 Same – – 
 rs13128039 G 0.0763 0.0003942 Same – – 
 rs13121382 G 0.1948 2.56E-06 Same – – 
 rs13119825 A 0.1497 0.0001882 Same – – 
 rs13117963 G 0.0913 0.0003584 Same – – 
 rs13116667 A 0.1177 0.000933 Same – – 
 rs13114658 G 0.0707 0.0006705 Same – – 
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rs13107566 A 0.0771 0.0002135 Same – – 
 rs13019524 T 0.0823 0.0003081 Same – – 
 rs13008704 C 0.0744 0.0003145 Same – – 
 rs12993399 G 0.0773 0.0008498 Same – – 
 rs12991989 C 0.098 1.49E-06 Same – – 
 rs12970058 C 0.0782 0.0004819 Same – – 
 rs12966713 C 0.0789 0.0005937 Same – – 
 rs12936839 G 0.0681 0.0007991 Same – – 
 rs12933988 G 0.1477 0.0002238 Same – – 
 rs12917875 T 0.0714 0.0004632 Same – – 
 rs12900128 C 0.0763 0.0004364 Same – – 
 rs12805818 G 0.1956 0.0008002 Same – – 
 rs12803794 G 0.1618 0.0004517 Same – – 
 rs12760630 A 0.1304 8.87E-11 Same – – 
 rs12739480 G 0.1016 0.0008327 Same – – 
 rs12733930 C 0.1019 3.18E-05 Same – – 
 rs12699203 G 0.0817 0.0005795 Same – – 
 rs12699137 A 0.1266 0.0002113 Same – – 
 rs12692738 C 0.0809 0.0006643 Same – – 
 rs12680985 C 0.0817 0.0002605 Same – – 
 rs12675482 C 0.0688 0.0008246 Same – – 
 rs12651348 G 0.1619 0.0004729 Same – – 
 rs12648289 A 0.1027 3.40E-05 Same – – 
 rs12634159 A 0.1833 0.0004992 Same – – 
 rs12621260 T 0.0993 0.0002596 Same – – 
 rs12610400 T 0.0796 0.00028 Same – – 
 rs12610304 C 0.0764 0.0003714 Same – – 
 rs12579648 G 0.1095 0.0003799 Same – – 
 rs12569209 A 0.0654 0.000878 Same – – 
 rs12550637 A 0.1322 0.0007816 Same – – 
 rs12549065 C 0.0784 0.0005413 Same – – 
 rs12533255 T 0.0872 0.0008112 Same – – 
 rs12526522 C 0.1809 0.0009076 Same – – 
 rs12517640 G 0.0835 0.0007697 Same – – 
 rs12500546 A 0.0698 0.000777 Same – – 
 rs12496661 G 0.0762 0.0006425 Same – – 
 rs12458508 C 0.0739 0.0005776 Same – – 
 rs12452256 C 0.0951 0.0005434 Same – – 
 rs12422762 C 0.122 0.0002054 Same – – 
 rs12415501 T 0.1441 9.04E-08 rs12253987 A 0.132 1.70E-07 
rs12406668 T 0.1442 4.92E-05 Same – – 
 rs12373097 T 0.1356 4.56E-06 Same – – 
 rs12370365 G 0.0967 4.35E-05 Same – – 
 rs12353280 T 0.1002 0.000237 Same – – 
 rs12325019 C 0.1572 0.0004565 Same – – 
 rs12284979 A 0.0989 0.0008668 Same – – 
 rs12282538 T 0.2263 6.29E-05 Same – – 
 rs12277614 A 0.1276 0.0009173 Same – – 
 rs12273915 T 0.1106 0.0001782 Same – – 
 rs1218582 A 0.1212 6.85E-09 Same – – 
 rs12160956 G 0.0697 0.0007948 Same – – 
 rs12149832 A 0.0698 0.0006778 Same – – 
 rs12135308 T 0.1139 0.0003854 Same – – 
 rs12129729 C 0.0737 0.0006107 Same – – 
 rs12122623 C 0.1674 0.0001725 Same – – 
 rs1205023 C 0.0826 0.0008063 Same – – 
 rs12047527 T 0.0735 0.0008813 Same – – 
 rs1203678 G 0.0715 0.0006396 Same – – 
 rs12031401 A 0.1031 0.0008578 Same – – 
 rs11977362 G 0.0743 0.0002148 Same – – 
 rs11959439 G 0.1055 0.0006381 Same – – 
 rs11957853 G 0.0735 0.0006144 Same – – 
 rs11897732 G 0.0713 0.0004167 Same – – 
 rs11869535 G 0.1686 0.0006289 Same – – 
 rs11857308 T 0.164 0.0002207 Same – – 
 rs11851570 T 0.0881 0.0006583 Same – – 
 rs11851174 T 0.1116 0.0001181 Same – – 
 rs11845845 A 0.1322 0.0005709 Same – – 
 rs11842292 T 0.0805 0.0001725 Same – – 
 rs11780023 T 0.0805 0.0001307 Same – – 
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rs11764828 A 0.1149 0.0007117 Same – – 
 rs11750489 G 0.0938 0.0008977 Same – – 
 rs11742784 A 0.1536 0.0005564 Same – – 
 rs11737595 C 0.1488 0.0008658 Same – – 
 rs11737346 C 0.1091 0.0004448 Same – – 
 rs11714471 G 0.0857 7.90E-05 Same – – 
 rs11697158 G 0.0743 0.0002943 Same – – 
 rs11690108 A 0.1881 0.0009061 Same – – 
 rs11687201 T 0.0859 0.0004058 Same – – 
 rs11652243 C 0.1479 0.0005433 Same – – 
 rs11627864 A 0.0863 7.86E-05 Same – – 
 rs11613339 A 0.0931 0.0003997 Same – – 
 rs11598558 G 0.122 0.000847 Same – – 
 rs1152591 A 0.1265 6.21E-10 Same – – 
 rs1150975 A 0.0768 0.0002637 Same – – 
 rs11265957 T 0.105 0.0008724 Same – – 
 rs11257794 G 0.1069 0.0003809 Same – – 
 rs11256613 G 0.0957 0.0002686 Same – – 
 rs1125322 G 0.1136 0.0001704 Same – – 
 rs11249478 T 0.1193 0.000564 Same – – 
 rs1122157 T 0.0871 8.51E-05 Same – – 
 rs11215000 T 0.0766 0.0008479 Same – – 
 rs11203855 G 0.1269 6.21E-05 Same – – 
 rs11200014 G 0.072 0.0007214 Same – – 
 rs11197047 T 0.0784 0.000929 Same – – 
 rs11131367 C 0.0681 0.0008139 Same – – 
 rs11103439 A 0.1365 0.0005334 Same – – 
 rs1109241 A 0.1638 0.0002143 Same – – 
 rs11085953 A 0.1197 0.0001203 Same – – 
 rs1108182 A 0.1202 0.0007987 Same – – 
 rs11081680 A 0.1278 0.0004198 Same – – 
 rs11067489 C 0.0839 6.36E-05 Same – – 
 rs11067228 G 0.0704 0.0004696 Same – – 
 rs11044373 T 0.0825 0.000666 Same – – 
 rs11043723 C 0.0809 0.000287 Same – – 
 rs11038581 T 0.1351 0.0007064 Same – – 
 rs11003402 G 0.0975 0.000991 rs4268426 T 0.1028 0.001925 
rs11002740 C 0.2983 0.000192 Same – – 
 rs10987905 C 0.0764 0.0005911 Same – – 
 rs10986333 T 0.0965 2.17E-06 Same – – 
 rs10947261 G 0.1627 2.68E-05 Same – – 
 rs10947260 T 0.1631 2.87E-05 Same – – 
 rs10927872 C 0.0675 0.0007785 Same – – 
 rs10919369 T 0.1136 2.55E-06 Same – – 
 rs10893224 G 0.1219 9.56E-05 Same – – 
 rs10876041 C 0.0723 0.0004396 Same – – 
 rs10873891 C 0.0863 0.0001626 Same – – 
 rs10863942 C 0.0756 0.0007836 Same – – 
 rs10860423 C 0.0755 0.0005078 Same – – 
 rs10853869 A 0.0821 0.0004268 Same – – 
 rs10849152 T 0.0837 4.92E-05 Same – – 
 rs10845399 G 0.0711 0.0007615 Same – – 
 rs10839849 A 0.1703 0.0002095 Same – – 
 rs10838436 T 0.0761 0.0001474 Same – – 
 rs10824026 A 0.1593 1.74E-08 Same – – 
 rs10821415 A 0.1235 7.88E-09 Same – – 
 rs10820859 A 0.1544 0.0004841 Same – – 
 rs10811889 T 0.1355 0.0002793 Same – – 
 rs10802521 G 0.089 0.0003087 Same – – 
 rs10800507 C 0.1024 8.76E-07 Same – – 
 rs10790497 A 0.0773 0.0004651 Same – – 
 rs10777685 G 0.0787 0.0004016 Same – – 
 rs10762941 A 0.0835 3.91E-05 Same – – 
 rs10739630 T 0.124 0.000414 Same – – 
 rs10519099 C 0.0802 0.0003183 Same – – 
 rs10518972 T 0.1102 0.0002787 Same – – 
 rs10515496 C 0.119 1.41E-06 Same – – 
 rs10514479 A 0.1527 0.0004469 Same – – 
 rs10513893 T 0.1335 0.0008148 Same – – 
 rs10507248 T 0.122 8.53E-08 Same – – 
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rs10506937 G 0.0682 0.000747 Same – – 
 rs10506569 C 0.0773 0.0001017 Same – – 
 rs10493679 A 0.2307 8.18E-05 Same – – 
 rs10483245 T 0.1304 0.0004691 Same – – 
 rs10466111 T 0.0989 0.0008499 Same – – 
 rs10465833 C 0.09 0.0007858 Same – – 
 rs10410258 T 0.0727 0.0009221 Same – – 
 rs10267684 T 0.097 4.12E-06 Same – – 
 rs10242171 G 0.1036 0.0004904 Same – – 
 rs10215877 T 0.0816 0.0009548 Same – – 
 rs10212121 A 0.0924 1.79E-05 Same – – 
 rs10189500 C 0.0693 0.0007051 Same – – 
 rs10187054 T 0.1138 0.0008774 Same – – 
 rs10178963 C 0.0706 0.0005022 Same – – 
 rs10177711 T 0.0723 0.0003784 Same – – 
 rs10171651 A 0.1118 0.0006836 Same – – 
 rs10137710 T 0.126 1.79E-06 Same – – 
 rs10136508 G 0.0778 0.0001522 Same – – 
 rs10095754 G 0.0802 0.0004232 Same – – 
 rs10081671 C 0.0786 0.0006838 Same – – 
 rs10067153 C 0.1031 0.0008213 Same – – 
 rs10063810 A 0.074 0.0002635 Same – – 
 rs10028494 A 0.1186 0.0003522 Same – – 
 rs10017096 A 0.0871 6.52E-05 Same – – 
 rs10011149 C 0.1206 0.0002152 Same – – 
  
 
Online Supplement—AF Genetic Risk, Incident AF, & Ischemic Stroke  
Page 17 of 27 
Supplemental Table 2. Distribution of atrial fibrillation genetic risk scores in a referent sample of 12,801 individuals from the 
Atherosclerosis Risk in Communities Study, Cardiovascular Health Study, and Framingham Heart Study. 
Genetic risk score PAFGen threshold Mean ± standard deviation 
11 SNPs <10-8 1.43 ± 0.40 
16 SNPs <5x10-8 1.95 ± 0.44 
18 SNPs <10-7 2.18 ± 0.45 
25 SNPs <10-6 3.29 ± 0.49 
45 SNPs <10-5 5.18 ± 0.62 
129 SNPs <10-4 14.19 ± 0.84 
719 SNPs <10-3 65.84 ± 1.67 
SNP=single nucleotide polymorphism 
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Supplemental Table 3. Model fit and discrimination with or without atrial fibrillation genetic 
risk in relation to incident atrial fibrillation.  
  MDCS 
Model / No. SNPs in GRS PAFGen  
threshold 
AIC C 
(95% CI) 
HL 
P-value 
CHARGE-AF score – 3223.1 0.753 
(0.720-0.786) 
0.99 
+ GRS (11 SNPs) <10-8 3216.8 0.760 
(0.727-0.793) 
0.93 
+ GRS (16 SNPs) <5x10-8 3212.8 0.763 
(0.730-0.796) 
0.98 
+ GRS (18 SNPs) <10-7 3212.6 0.764 
(0.731-0.796) 
0.87 
+ GRS (25 SNPs) <10-6 3208.3 0.767 
(0.734-0.799) 
0.87 
+ GRS (45 SNPs) <10-5 3207.5 0.768 
(0.735-0.801) 
0.96 
+ GRS (129 SNPs) <10-4 3204.7 0.770 
(0.738-0.802) 
0.62 
+ GRS (719 SNPs) <10-3 3218.9 0.758 
(0.725-0.792) 
0.56 
  MESA 
Model / No. SNPs in GRS PAFGen  
threshold 
AIC C 
(95% CI) 
HL 
P-value 
CHARGE-AF score – 1859.3 0.802 
(0.755-0.850) 
0.97 
+ GRS (11 SNPs) <10-8 1855.3 0.806 
(0.758-0.853) 
0.99 
+ GRS (16 SNPs) <5x10-8 1848.3 0.809 
(0.762-0.857) 
0.97 
+ GRS (18 SNPs) <10-7 1846.9 0.809 
(0.761-0.856) 
0.97 
+ GRS (25 SNPs) <10-6 1845.0 0.808 
(0.761-0.855) 
0.93 
+ GRS (45 SNPs) <10-5 1848.0 0.810 
(0.762-0.857) 
0.99 
+ GRS (129 SNPs) <10-4 1849.2 0.811 
(0.764-0.858) 
0.98 
+ GRS (719 SNPs) <10-3 1857.2 0.804 
(0.756-0.852) 
0.73 
  PREVEND 
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Model / No. SNPs in GRS PAFGen  
threshold 
AIC C 
(95% CI) 
HL 
P-value 
CHARGE-AF score  – 485.2 0.756 
(0.657-0.854) 
0.43 
+ GRS (11 SNPs) <10-8 470.1 0.804 
(0.711-0.898) 
0.88 
+ GRS (16 SNPs) <5x10-8 467.0 0.818 
(0.732-0.904) 
0.24 
+ GRS (18 SNPs) <10-7 466.8 0.817 
(0.728-0.907) 
0.25 
+ GRS (25 SNPs) <10-6 460.9 0.820 
(0.739-0.900) 
0.50 
+ GRS (45 SNPs) <10-5 456.6 0.821 
(0.737-0.905) 
0.14 
+ GRS (129 SNPs) <10-4 469.2 0.790 
(0.708-0.872) 
0.12 
+ GRS (719 SNPs) <10-3 474.7 0.795 
(0.715-0.875) 
0.83 
  PROSPER 
Model / No. SNPs in GRS PAFGen  
threshold 
AIC C 
(95% CI) 
HL 
P-value 
CHARGE-AF score  – 8267.7 0.615 
(0.590-0.640) 
<1.0x10-4 
+ GRS (11 SNPs) <10-8 8260.9 0.621 
(0.596-0.645) 
<1.0x10-4 
+ GRS (16 SNPs) <5x10-8 8253.7 0.624 
(0.600-0.649) 
<1.0x10-4 
+ GRS (18 SNPs) <10-7 8251 0.625 
(0.601-0.650) 
<1.0x10-4 
+ GRS (25 SNPs) <10-6 8248.3 0.628 
(0.603-0.653) 
<1.0x10-4 
+ GRS (45 SNPs) <10-5 8246.9 0.629 
(0.604-0.654) 
<1.0x10-4 
+ GRS (129 SNPs) <10-4 8246.3 0.629 
(0.604-0.654) 
<1.0x10-4 
+ GRS (719 SNPs) <10-3 8255.5 0.627 
(0.602-0.651) 
<1.0x10-4 
  BioVU 
Model / No. SNPs in GRS PAFGen  
threshold 
AIC C 
(95% CI) 
HL 
P-value 
CHARGE-AF score  – 3207.0 0.671 0.73 
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(0.637-0.704) 
+ GRS (11 SNPs) <10-8 3197.9 0.684 
(0.652-0.716) 
0.70 
+ GRS (16 SNPs) <5x10-8 3196.5 0.684 
(0.653-0.716) 
0.70 
+ GRS (18 SNPs) <10-7 3196.6 0.684 
(0.653-0.716) 
0.72 
+ GRS (25 SNPs) <10-6 3196.1 0.685 
(0.653,0.717) 
0.43 
+ GRS (45 SNPs) <10-5 3200.7 0.681 
(0.649-0.714) 
0.71 
+ GRS (129 SNPs) <10-4 3205.7 0.674 
(0.641-0.707) 
0.63 
+ GRS (719 SNPs) <10-3 3206.1 0.674 
(0.641-0.707) 
0.37 
All scores with SNPs are adjusted for the CHARGE-AF clinical score.22-25 
SNP=single nucleotide polymorphism; GRS=genetic risk score; AIC = Akaike’s Information 
Criterion; HL = Hosmer-Lemeshow 
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Supplemental Table 4. Association of atrial fibrillation genetic risk with atrial fibrillation, ischemic stroke, and cardioembolic stroke in 
MGH-GASROS. 
 
 Atrial fibrillation All ischemic stroke Cardioembolic stroke 
 No. cases 87 509 202 
 
No. controls 3,450 3,028 3,028 
No. SNPs in GRS  
(PAFGen 
threshold*) 
Mean ± SD of 
GRS 
OR (95% CI)  
per 1-unit change 
in GRS P 
OR (95% CI)  
per 1-unit change 
in GRS P 
OR (95% CI)  
per 1-unit change 
in GRS P 
11 (<10-8) 
1.35±0.42 
1.81  
(1.02-3.23) 0.04 
1.46  
(1.06-2.02) 0.02 
1.35  
(0.86-2.13) 0.19 
16 (<5x10-8) 
1.87±0.45 
1.54  
(0.90-2.64) 0.12 
1.35  
(1.00-1.82) 0.05 
1.31  
(0.86-2.00) 0.20 
18 (<10-7) 
2.04±0.46 
1.62  
(0.96-2.74) 0.07 
1.36  
(1.01-1.83) 0.04 
1.37  
(0.90-2.07) 0.14 
25 (<10-6) 
3.05±0.50 
1.71  
(1.06-2.77) 0.03 
1.31  
(1.00-1.72) 0.05 
1.41  
(0.97-2.06) 0.08 
45 (<10-5) 
4.74±0.62 
1.66  
(1.13-2.44) 9.4x10-3 
1.30  
(1.05-1.62) 0.02 
1.43  
(1.06-1.93) 0.19 
127 (<10-4) 
11.63±0.82 
1.75  
(1.29-2.37) 3.1x10-4 
1.34  
(1.14-1.58) 4.9x10-4 
1.45  
(1.16-1.83) 1.4x10-3 
701 (<10-3) 
54.74±1.59 
1.24  
(1.05-1.47) 0.01 
1.24  
(1.13-1.36) 5.4x10-6 
1.31  
(1.15-1.50) 3.7x10-5 
All models adjusted for age, sex, principal components of ancestry, and genotyping platform. For each analysis, the GRS with the 
smallest P value is bolded. 
*Refers to the P-value for association between each SNP included in the genetic risk score and atrial fibrillation in an independent 
genome-wide association study of atrial fibrillation.26 SNP totals may not equal those used in the incident atrial fibrillation analysis 
since some SNPs were unavailable, in which case proxies were used when available (Supplemental Table 1). 
GRS=genetic risk score, SNP=single nucleotide polymorphism, HR=hazard ratio, CI=confidence interval. 
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Supplemental Table 5. Association of atrial fibrillation genetic risk with ischemic stroke and cardioembolic stroke in MGH-
GASROS in subjects without known AF. 
  All ischemic stroke Cardioembolic stroke 
 No. cases 422 132 
 No. controls 3,028 3,028 
No. SNPs in GRS  
(PAFGen threshold†) 
Mean ± SD of GRS OR (95% CI)  
per 1-unit change in GRS 
P OR (95% CI)  
per 1-unit change in GRS 
P 
11 (<10-8) 1.34±0.41 1.48  
(1.07-2.05) 
0.02 1.32  
(0.82-2.14) 
0.25 
16 (<5x10-8) 1.86±0.45 1.36  
(1.01-1.84) 
0.05 1.31  
(0.84-2.05) 
0.23 
18 (<10-7) 2.04±0.45 1.36  
(1.01-1.84) 
0.04 1.35  
(0.87-2.10) 
0.19 
25 (<10-6) 3.05±0.49 1.30  
(0.99-1.71) 
0.06 1.40  
(0.94-2.09) 
0.10 
45 (<10-5) 4.73±0.62 1.28  
(1.03-1.59) 
0.03 1.41  
(1.03-1.93) 
0.04 
127 (<10-4) 11.61±0.81 1.30  
(1.10-1.53) 
2.4x10-3 1.37  
(1.07-1.75) 
0.01 
701 (<10-3) 54.68±1.55 1.22  
(1.11-1.34) 
3.10x10-5 1.27  
(1.11-1.46) 
7.2x10-4 
All models adjusted for age, sex, principal components of ancestry, and genotyping platform. For each analysis, the GRS 
with the smallest P value is bolded. 
*Refers to the P-value for association between each SNP included in the genetic risk score and atrial fibrillation in an 
independent genome-wide association study of atrial fibrillation.26 SNP totals may not equal those used in the incident atrial 
fibrillation analysis since some SNPs were unavailable, in which case proxies were used when available (Supplemental 
Table 1). 
GRS=genetic risk score, SNP=single nucleotide polymorphism, HR=hazard ratio, CI=confidence interval. 
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Supplemental Figure 1. Associations between atrial fibrillation genetic risk and incident atrial fibrillation in five prospective studies 
including 18,919 individuals. 
 
SNPs included in scores were derived using different thresholds of association between each SNP and atrial fibrillation in an earlier, 
independent study26 (11 SNPs [P<1x10-8], 16 SNPs [P<5x10-8], 16 SNPs [P<1x10-7], 18 SNPs [P<1x10-6], 25 SNPs [P<1x10-5], 45 
SNPs [P<1x10-4], 129 SNPs [P<1x10-3], and 719 SNPs [P<1x10-3]. Hazard ratios with 95% confidence intervals are displayed. All 
scores are adjusted for age, height, weight, systolic and diastolic blood pressure, history of smoking, antihypertensive medication 
use, diabetes status, heart failure status, myocardial infarction status, and electrocardiographic left ventricular hypertrophy and PR 
interval as noted in the text. SD=standard deviation; SNP=single nucleotide polymorphism.  
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Supplemental Figure 2. Five-year cumulative incidence of atrial fibrillation according to clinical 
and genetic risk in MDCS. 
 
The five-year cumulative incidence of atrial fibrillation was plotted using the Kaplan-Meier 
method based on dichotomized clinical risk in blue. The incremental contribution to atrial 
fibrillation risk estimation of dichotomized genetic risk beyond clinical risk is overlaid on the plot 
in red. Risk scores were calculated for each patient as described in the manuscript and were 
dichotomized at the median value.  
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